Jackson Grant Investment Advisers Inc. Has $29,000 Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Jackson Grant Investment Advisers Inc. cut its stake in Edwards Lifesciences Co. (NYSE:EW) by 29.7% in the 4th quarter, Holdings Channel.com reports. The fund owned 385 shares of the medical research company’s stock after selling 163 shares during the quarter. Jackson Grant Investment Advisers Inc.’s holdings in Edwards Lifesciences were worth $29,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in EW. Moneta Group Investment Advisors LLC raised its holdings in Edwards Lifesciences by 104,971.3% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company’s stock valued at $1,148,938,000 after acquiring an additional 15,384,593 shares in the last quarter. Norges Bank bought a new position in shares of Edwards Lifesciences in the 4th quarter valued at $658,390,000. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST increased its stake in shares of Edwards Lifesciences by 440.0% in the 3rd quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 3,510,000 shares of the medical research company’s stock valued at $243,173,000 after purchasing an additional 2,860,000 shares during the last quarter. AustralianSuper Pty Ltd bought a new position in shares of Edwards Lifesciences in the 4th quarter valued at $168,519,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its stake in shares of Edwards Lifesciences by 655.9% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,325,457 shares of the medical research company’s stock valued at $173,502,000 after purchasing an additional 2,017,801 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the sale, the chief financial officer now owns 19,248 shares of the company’s stock, valued at $1,506,925.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares of the company’s stock, valued at $1,506,925.92. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 1,715 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $90.98, for a total transaction of $156,030.70. Following the transaction, the vice president now directly owns 17,213 shares of the company’s stock, valued at approximately $1,566,038.74. The disclosure for this sale can be found here. Insiders have sold a total of 194,004 shares of company stock valued at $17,166,254 over the last quarter. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Down 0.6 %

NYSE:EW traded down $0.51 on Friday, hitting $85.94. The stock had a trading volume of 3,895,701 shares, compared to its average volume of 2,826,513. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. The stock has a market cap of $51.73 billion, a price-to-earnings ratio of 37.37, a PEG ratio of 4.26 and a beta of 1.05. The company has a fifty day moving average price of $90.15 and a two-hundred day moving average price of $78.37. Edwards Lifesciences Co. has a 1-year low of $60.57 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, meeting analysts’ consensus estimates of $0.64. The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The company’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.64 EPS. Equities research analysts expect that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Mizuho boosted their price objective on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. Stifel Nicolaus boosted their price objective on Edwards Lifesciences from $70.00 to $83.00 and gave the stock a “hold” rating in a research report on Wednesday, February 7th. OTR Global upgraded Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Morgan Stanley boosted their price objective on Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research report on Thursday, March 21st. Finally, Oppenheimer boosted their price objective on Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, March 18th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $91.73.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.